Abstract
Objectives
The aim was to describe the status of patients with urea cycle disorders (UCD) at the latest long-term clinical follow-up of treatment with a new taste-masked formulation of sodium phenylbutyrate (NaPB) granules (Pheburane). These patients are a subset of those treated under a cohort temporary utilisation study (ATU) previously reported and now followed for 2 years.
Methods
From a French cohort temporary utilization authorization (ATU) set up to monitor the use of Pheburane on a named-patient basis in UCD patients in advance of its marketing authorization, a subset of patients were followed up in the long term. Data on demographics, dosing characteristics of NaPB, concomitant medications, adverse events and clinical outcomes were collected at a follow-up visit after 1–2 years of treatment with the drug administered under marketing conditions. This paper reports on the subset of patients who were included in further long-term follow-up at the principal recruiting metabolic reference center involved in the original cohort.
Results
No episode of metabolic decompensation was observed over a treatment period ranging from 8 to 30 months with Pheburane, and the range of ammonia and glutamine levels continued to improve and remained within the normal range, thus adding valuable longer-term feedback to the original ATU report. In all, no adverse events were reported with Pheburane treatment. These additional data demonstrate the maintenance of the safety and efficacy of Pheburane over time.
Conclusions
The recently developed taste-masked formulation of NaPB granules (Pheburane) improved the quality of life for UCD patients. The present post-marketing report on the use of the product confirms the original observations of improved compliance, efficacy and safety with this taste-masked formulation of NaPB.
This is a preview of subscription content, log in via an institution to check access.
References
Kibleur Y, Dobbelaere D, Barth M, Brassier A, Guffon N. Results from a nationwide cohort temporary utilization authorization (ATU) survey of patients in France treated with Pheburane ® (sodium phenylbutyrate) taste-masked granules. Paediatr Drugs. 2014;16(5):407–15.
Diaz GA, Krivitzky LS, Mokhtarani M, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology. 2013;57(6):2171–9.
Cederbaum S, Lemons C, Batshaw ML. Alternative pathway or diversion therapy for urea cycle disorders now and in the future. Mol Genet Metab. 2010;100(3):219–20.
Authors contributions
Both authors made substantial contributions to the acquisition and interpretation of data for the work, revised the manuscript critically, agreed to give final approval of the version to be published and are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
YK is the medical director at Lucane Pharma, the marketing authorization holder for Pheburane.
The other author (NG) has no competing interest.
Funding
This work received no specific grant from any funding agency in the public, commercial or not-for-profit sector.
Rights and permissions
About this article
Cite this article
Kibleur, Y., Guffon, N. Long-Term Follow-Up on a Cohort Temporary Utilization Authorization (ATU) Survey of Patients Treated with Pheburane (Sodium Phenylbutyrate) Taste-Masked Granules. Pediatr Drugs 18, 139–144 (2016). https://doi.org/10.1007/s40272-015-0159-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-015-0159-8